We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced data from the pivotal phase III PSMAfore study, which evaluated its cancer drug Pluvicto for treating patients with PSMA–positive metastatic castration-resistant prostate cancer (mCRPC) following treatment with androgen-receptor pathway inhibitor (ARPI) therapy.
Data from the study showed that treatment with Pluvicto led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS), the study’s primary endpoint, in the above-mentioned patient group, versus a change in ARPI.
With the above-mentioned data, Pluvicto has now become the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
This is the second phase III study on Pluvicto, which has met the primary endpoint. Earlier, the phase III VISION study showed that patients with PSMA–positive mCRPC, who received Pluvicto plus standard of care after being treated with other anticancer treatments like ARPI and taxane-based chemotherapy, experienced a statistically significant reduction in risk of death.
NVS plans to submit the findings from the PSMAfore study at an upcoming medical conference and file for label expansion approval for Pluvicto to regulatory authorities in 2023.
Shares of Novartis have inched up 2.9% so far this year compared with the industry’s increase of 11.5%.
Image Source: Zacks Investment Research
At present, Pluvicto is approved to treat patients with PSMA–positive mCRPC who have been treated with ARPI and taxane-based chemotherapy in the United States and some other countries based on data from the VISION study. It was approved in the United States in March and is also approved in the U.K. and Canada,
In October 2022, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency adopted a positive opinion of Pluvicto. The CHMP recommended granting marketing authorization to Pluvicto in combination with androgen deprivation therapy with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy.
A final decision from the European Commission is expected shortly.
Pluvicto is also being evaluated in additional phase III studies in earlier lines of treatment for metastatic prostate cancer. Approval for an additional patient population is likely to boost the growth potential of the drug, which has already witnessed an encouraging uptake so far.
Loss per share estimates for ASLAN Pharmaceuticals have narrowed 6.1% for 2022 and 5.7% for 2023 in the past 60 days.
Earnings of ASLAN Pharmaceuticals surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ASLN witnessed an earnings surprise of 1.64% on average.
Loss per share estimates for Aeglea BioTherapeutics have narrowed 7.3% for 2022 and 13.2% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. AGLE witnessed an earnings surprise of 3.60% on average.
Loss per share estimates for Immunocore have narrowed 39.7% for 2022 and 39.4% for 2023 in the past 60 days.
Earnings of Immunocore surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. IMCR witnessed an earnings surprise of 68.34% on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
Novartis AG (NVS - Free Report) announced data from the pivotal phase III PSMAfore study, which evaluated its cancer drug Pluvicto for treating patients with PSMA–positive metastatic castration-resistant prostate cancer (mCRPC) following treatment with androgen-receptor pathway inhibitor (ARPI) therapy.
Data from the study showed that treatment with Pluvicto led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS), the study’s primary endpoint, in the above-mentioned patient group, versus a change in ARPI.
With the above-mentioned data, Pluvicto has now become the first PSMA-targeted radioligand therapy to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
This is the second phase III study on Pluvicto, which has met the primary endpoint. Earlier, the phase III VISION study showed that patients with PSMA–positive mCRPC, who received Pluvicto plus standard of care after being treated with other anticancer treatments like ARPI and taxane-based chemotherapy, experienced a statistically significant reduction in risk of death.
NVS plans to submit the findings from the PSMAfore study at an upcoming medical conference and file for label expansion approval for Pluvicto to regulatory authorities in 2023.
Shares of Novartis have inched up 2.9% so far this year compared with the industry’s increase of 11.5%.
Image Source: Zacks Investment Research
At present, Pluvicto is approved to treat patients with PSMA–positive mCRPC who have been treated with ARPI and taxane-based chemotherapy in the United States and some other countries based on data from the VISION study. It was approved in the United States in March and is also approved in the U.K. and Canada,
In October 2022, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency adopted a positive opinion of Pluvicto. The CHMP recommended granting marketing authorization to Pluvicto in combination with androgen deprivation therapy with or without androgen receptor (AR) pathway inhibition for the treatment of adult patients with progressive PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy.
A final decision from the European Commission is expected shortly.
Pluvicto is also being evaluated in additional phase III studies in earlier lines of treatment for metastatic prostate cancer. Approval for an additional patient population is likely to boost the growth potential of the drug, which has already witnessed an encouraging uptake so far.
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech sector are ASLAN Pharmaceuticals Limited (ASLN - Free Report) , Aeglea BioTherapeutics, Inc. and Immunocore Holdings plc (IMCR - Free Report) , all carrying a Zacks Rank #2 (Buy) at present.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for ASLAN Pharmaceuticals have narrowed 6.1% for 2022 and 5.7% for 2023 in the past 60 days.
Earnings of ASLAN Pharmaceuticals surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. ASLN witnessed an earnings surprise of 1.64% on average.
Loss per share estimates for Aeglea BioTherapeutics have narrowed 7.3% for 2022 and 13.2% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. AGLE witnessed an earnings surprise of 3.60% on average.
Loss per share estimates for Immunocore have narrowed 39.7% for 2022 and 39.4% for 2023 in the past 60 days.
Earnings of Immunocore surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. IMCR witnessed an earnings surprise of 68.34% on average.